Surgery pp 287-304 | Cite as

Severe Sepsis and Septic Shock

  • Steven M. Opal


This chapter reviews the remarkable recent advances in the understanding of the molecular basis that underlies the pathophysiology of sepsis. This knowledge has improved diagnostic techniques and introduced new therapeutic agents into the standard management of patients with severe sepsis/septic shock. The current treatment regimens for sepsis are discussed, and the evidence to support each major treatment strategy is outlined in detail. Research priorities to further the optimal management of septic shock in the future are highlighted.


Nitric Oxide Septic Shock Severe Sepsis Acute Lung Injury Migration Inhibitory Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Poeze M, Ramsay G, Gerlach H, et al. International sepsis survey: A study of doctor’s knowledge and perception about sepsis. Crit Care 2004;8:409–413.Google Scholar
  2. 2.
    Levy M, Ramsey G, Fink M, et al. The 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250–1256.PubMedGoogle Scholar
  3. 3.
    Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock. Crit Care Med 2004;32:858–871.PubMedGoogle Scholar
  4. 4.
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310.PubMedGoogle Scholar
  5. 5.
    Martin GS, Mannino DM, Eaton S, et al. Epidemiology of sepsis in the United States from 1979–2000. N Engl J Med 2003;348:1546–1554.PubMedGoogle Scholar
  6. 6.
    Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from international multi-center cohort study. Intensive Care Med 2002;28:108–121.PubMedGoogle Scholar
  7. 7.
    Valles J, Leon C, Alvarez-Lerma F. Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of the Sociedad Espanola de Medicina Intensiva Unidades Coronarias (SEMIUC). Clin Infect Dis 1997;24:387–395.PubMedGoogle Scholar
  8. 8.
    Friedman G, Silva E, Vincent J-L. Has the mortality of septic shock changed with time? Crit Care Med 1998;26:2078–2086.PubMedGoogle Scholar
  9. 9.
    Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in eight academic medical centers. JAMA 1997;278:234–240.PubMedGoogle Scholar
  10. 10.
    Brun-Buisson C, Meshaka P, Pinton P, et al. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. Intensive Care Med 2004;30:580–588.PubMedGoogle Scholar
  11. 11.
    Opal SM, Esmon C. Functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003;7:23–38.PubMedGoogle Scholar
  12. 12.
    Hund E. Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001;248:929–934.PubMedGoogle Scholar
  13. 13.
    Brun-Buisson C, Roudot-Thoraval F, Girou E, et al. The costs of septic syndromes in the intensive care unit and the influence of hospital-acquired sepsis. Intensive Care Med 2003;29:1464–1471.PubMedGoogle Scholar
  14. 14.
    Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. IE. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980;68:332–343.PubMedGoogle Scholar
  15. 15.
    Pittet D, Thiívent B, Wenzel RP, et al. Importance of pre-existing co-morbidities for prognosis of septicemia in critically ill patients. Intensive Care Med 1993;19:265–272.PubMedGoogle Scholar
  16. 16.
    Opal SM, Maki D, Larosa S, et al. Systemic host response to sepsis based upon the infectious microorganism and effects of drotrecogin alfa activated. Clin Infect Dis 2003;37:50–58.PubMedGoogle Scholar
  17. 17.
    Cohen J, Brun-Buisson C, Torres A, et al. Diagnosis of infection in sepsis: an evidence-based review. Crit Care Med 2004;32:S466–S494.PubMedGoogle Scholar
  18. 18.
    Ely EW, Wheeler AP, Thompson BT, et al. Recovery rate and prognosis in older persons who develop acute lung injury and the acute respiratory distress syndrome. Ann Intern Med 2002;136:25–29.PubMedGoogle Scholar
  19. 19.
    Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002;34;730–751.PubMedGoogle Scholar
  20. 20.
    Styrt B. Infection associated with asplenia: risks, mechanisms and prevention. Am J Med 1990;88:33N–42N.PubMedGoogle Scholar
  21. 21.
    Sorensen TIA, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727–732.PubMedGoogle Scholar
  22. 22.
    Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-y receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941–1949.PubMedGoogle Scholar
  23. 23.
    Beutler B. Science review: key inflammatory and stress pathways in critical illness. Crit Care 2003;7:39–46.PubMedGoogle Scholar
  24. 24.
    Lorenz E, Mira J-P, Frees KG, Schwartz DA. Relevance of mutations in the TLR4-receptor in patients with gram-negative septic shock. Arch Intern Med 2002;162:1028–1031.PubMedGoogle Scholar
  25. 25.
    Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism with the CD 14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002;30:969–973.PubMedGoogle Scholar
  26. 26.
    Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD 14 polymorphisms are associated with increased risk of gram-negative infections J Infect Dis 2002;185:1522–1525.Google Scholar
  27. 27.
    Mira JP, Cariou A, Grail F et al. Association of TNF2, a TNFα promoter polymorphism, with septic shock susceptibility and mortality. JAMA 1999;282:561–568.PubMedGoogle Scholar
  28. 28.
    Read RC, Camp NJ, Di Giovine FS, et al. An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis 2000;182:1557–1560.PubMedGoogle Scholar
  29. 29.
    Nadel S, Newport MJ, Booy R, et al. Variation in the tumor necrosis factor-α gene promoter region may be associated with death from meningococcal disease. J Infect Dis 1996;174:878–880.PubMedGoogle Scholar
  30. 30.
    Smirnova I, Mann N, Dols A, et al. Assay of locus-specific genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci U S A 2003;100:6075–6080.PubMedGoogle Scholar
  31. 31.
    O’Keefe G, Hybki DL, Munford RS. The G→ a single nucleotide polymorphism at the −308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis. J Trauma 2002;52:817–826.PubMedGoogle Scholar
  32. 32.
    Stuber F, Petersen M, Bokelmann F, et al. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome patients with severe sepsis. Crit Care Med 1996;24:381–384.PubMedGoogle Scholar
  33. 33.
    Schlüter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (−174G/C) on the incidence and outcome of sepsis. Crit Care Med 1002;30:32–37.Google Scholar
  34. 34.
    Bone RC: Gram-positive organisms in sepsis. Arch Intern Med 1994;154:26–31.PubMedGoogle Scholar
  35. 35.
    Danner RL, Elin RJ, Hosseini JM, et al. Endotoxemia in human septic shock. Chest 1991;99:169–175.PubMedGoogle Scholar
  36. 36.
    Rietschel ET, Kirikae T, Schade FU, et al. Bacterial endotoxin: molecular mechanisms of structure to activity and function. FASEB J 1994;218:217–225.Google Scholar
  37. 37.
    Pridmore AC, Wyllie DH, Abdillahi F, et al. A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR)2 but not via TLR4/MD2. J Infect Dis 2001;183:89–96.PubMedGoogle Scholar
  38. 38.
    Medzhitov R, Janeway, C. Innate immunity. N Engl J Med 2000;343:338–344.PubMedGoogle Scholar
  39. 39.
    Fenton MJ, Golenbock DT.LPS-binding proteins and receptors. J Leukoc Biol 1998;64:25–32.PubMedGoogle Scholar
  40. 40.
    Pugin J, Heumann ID, Tomasz A, et al. CD 14 is a pattern recognition receptor. Immunity 1994;1:509–516.PubMedGoogle Scholar
  41. 41.
    Lin Y, Leach WJ, Ammons WS. Synergistic effect of a recombinant N-terminal fragment of bactericidal/permeability increasing protein and cefamandole in treatment of rabbit gram-negative sepsis. Antimicrobial Agents Chemother 1996;40:65–69.Google Scholar
  42. 42.
    Levin M, Qunit PA, Goldstein B, et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet 200;356:961–967.Google Scholar
  43. 43.
    Poltorak A, He X, Smirnova I, et al. Defective signaling in C3H/ HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085–2088.PubMedGoogle Scholar
  44. 44.
    Takeuchi O, Hoshino K, Kawai T, et al. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999;11:443.PubMedGoogle Scholar
  45. 45.
    Brightbill HD, Libraty DH, Krutzik SR, et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 1999;285:732–735.PubMedGoogle Scholar
  46. 46.
    Cristofaro P, Opal S. The human toll-like receptors as a therapeutic target. Expert Opin Therapeutic Targets. 2003;7:603–612.Google Scholar
  47. 47.
    Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526–1529.PubMedGoogle Scholar
  48. 48.
    Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004;303:1522–1526.PubMedGoogle Scholar
  49. 49.
    Wolbink GJ, Bossink AW, Groeneveld AB, et al. Complement activation in patients with sepsis is in part mediated by C-reactive protein. J Infect Dis 1998;177:81–87.PubMedGoogle Scholar
  50. 50.
    Roy S, Knox K, Griffiths D, et al. MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 2002;359:1569–1573.PubMedGoogle Scholar
  51. 51.
    Landmann R, Müller B, Zimmerli W. CD 14, new aspects of ligand and signal diversity. Microb Infect 2000;2:295–304.Google Scholar
  52. 52.
    Nau GJ, Richmond JF, Schlesinger A, et al. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A 2002;99:1503–1508.PubMedGoogle Scholar
  53. 53.
    Boldrick JC, Alizadeh AA, Diehn M, et al. Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A 2002;99:972–977.PubMedGoogle Scholar
  54. 54.
    Means TK, Golenbock DT, Fenton MJ. The biology of toll-like receptors. Cytokine Growth Factor Rev 2000;11:219–232.PubMedGoogle Scholar
  55. 55.
    Hemmi H, Osamu T, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature 2000;408:740–744.PubMedGoogle Scholar
  56. 56.
    Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double stranded RNA and activation of NFKB by Toll-like receptor 3. Nature 2001;413:732–738.PubMedGoogle Scholar
  57. 57.
    Hayayashi F, Smith KD, Ozinski A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001;420:1099–1103.Google Scholar
  58. 58.
    Choi Y, Lafferty JA, Clements JRL. Selective expansion of T cells expressing Vb2 in toxic shock syndrome. J Exp Med 1990;172:981.PubMedGoogle Scholar
  59. 59.
    Hotchkiss RS, Karl IE. The pathology and treatment of sepsis. N Engl J Med 2003;348:138–150.PubMedGoogle Scholar
  60. 60.
    Florquine S, Goldman M: Immunoregulatory mechanisms of T-cell-dependent shock induced by bacterial superantigen in mice. Infect Immun 1996;64:3443.Google Scholar
  61. 61.
    Kusunoki T, Hailman E, Juan TS-C, et al. Molecules from Staphylococcus aureus that bind CD 14 and stimulate innate immune responses. J Exp Med 995,182:1673.Google Scholar
  62. 62.
    Opal SM, Huber CE. Sepsis. Sci Am Med. 2001;30:1–17.Google Scholar
  63. 63.
    Opal SM, Scannon PJ, Vincent JL, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999;180:1584–1589.PubMedGoogle Scholar
  64. 64.
    Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1998;234:470–474.Google Scholar
  65. 65.
    Bauer KA, ten Cate H, Barzegar S, et al. Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. Blood 1989;74:165.PubMedGoogle Scholar
  66. 66.
    Fisher CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12–21.PubMedGoogle Scholar
  67. 67.
    Dinarello CA, Gelfand JA, Wolff SM. Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 1993;269:1825–1832.Google Scholar
  68. 68.
    Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med 1998;338:436–442.PubMedGoogle Scholar
  69. 69.
    Falk LA, McNally R, Perera PY, et al. LPS-inducible responses in severe combined immunodeficiency (SCID) mice. J Endotoxin Res 1995;2:273.Google Scholar
  70. 70.
    Szabo SJ, Dinghe AS, Gubler U, et al. Regulation of the interleukin (IL)-12Rb2 subunit expression in developing T helper 1 (Thl) and Th2 cells. J Exp Med 1997;185:817.PubMedGoogle Scholar
  71. 71.
    Schneider C, von Aulock S, Siegfried Z, et al. Perioperative recombinant human granulocyte colony-stimulating factor (filgrastim) treatment prevents immunoinflammatory dysfunction associated with major surgery. Ann Surg 2004;239:75–81.PubMedGoogle Scholar
  72. 72.
    Hotchkiss RS, Swanson PE, Freeman BD, et al. Apototic cell death in patients with sepsis, shock and multiple organ dysfunction. Crit Care Med 1999;27:1230–1251.PubMedGoogle Scholar
  73. 73.
    Kell M, Ungethüm U, Steckholzer U, et al. Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood 1997;90:3356–3363.Google Scholar
  74. 74.
    van Deventer SJH, Buller HR, ten Cate JW, et al. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990;76:2520–2526.PubMedGoogle Scholar
  75. 75.
    Greenberger MJ, Strieter RM, Kunkel SL, et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995;155:722–729.PubMedGoogle Scholar
  76. 76.
    MacMicking J, Xie QM, Nathan C. Nitric oxide and macrophage function. Annu Rev Microbiol 1997;15:323–350.Google Scholar
  77. 77.
    Shenep JL, Toumanen E. Prospective: targeting nitric oxide in the adjuvant therapy of sepsis in meningitis. J Infect Dis 1998;177:766–771.PubMedGoogle Scholar
  78. 78.
    Liaudet L Poly (adenosine 5′phosphate) ribose polymerase activation as a cause of metabolic dysfunction in critical illness. Curr Opin Clin Nutr Metab Care 2002;5:175–184.PubMedGoogle Scholar
  79. 79.
    Vervloet MG, Thijs LG, Hack CE. Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock. Semin Thromb Hemost 1998;24:33–44.PubMedGoogle Scholar
  80. 80.
    McGilvray ID, Rotstein OD. Role of the coagulation system in the local and systemic inflammatory response. World J Surg 1998;22:179–86.PubMedGoogle Scholar
  81. 81.
    Aird W. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003;101:3765–3777.PubMedGoogle Scholar
  82. 82.
    Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic abnormalities in sepsis and its relation to outcome. Chest 1993;103:1536–1542.PubMedGoogle Scholar
  83. 83.
    Coughlin SR. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 1994;4:77–83.Google Scholar
  84. 84.
    Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586–592.PubMedGoogle Scholar
  85. 85.
    Abraham E, Reinhart K, Opal SM, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003;290:238–251.PubMedGoogle Scholar
  86. 86.
    Bernard GR, Vincent JL, Laterre PF, et al. Safety and efficacy of activated protein C for severe sepsis. N Engl J Med 2001;344:699–709.PubMedGoogle Scholar
  87. 87.
    Warren BL, Eid A, Singer P, et al. High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 2001;286:1869–1878.PubMedGoogle Scholar
  88. 88.
    Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199–11203.PubMedGoogle Scholar
  89. 89.
    Corrigan JJ Jr. Heparin therapy in bacterial septicemia. J Pediatr 1977; 91:695–700.PubMedGoogle Scholar
  90. 90.
    Hoffmann JN, Vollmar B, Inthorn D et al. The thrombin antagonist hirudin fails to inhibit endotoxin-induced leukocyte/ endothelial cell interaction and microvascular perfusion failure. Shock 2000;14:528–534.PubMedGoogle Scholar
  91. 91.
    Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999;340:207–214.PubMedGoogle Scholar
  92. 92.
    Esmon CT. Why do animal models (sometimes) fail to mimic human sepsis? Crit Care Med 2004;32:S219–S22.PubMedGoogle Scholar
  93. 93.
    Roger T, Froidevaux C, Martin C, et al. Macrophage migration inhibitory factor (MIF) regulates host responses to endotoxin through modulation of Toll-like receptor 4 (TLR4). J Endotoxin Res 2003;9:119–123.PubMedGoogle Scholar
  94. 94.
    Garner LB, Willis MS, Carlson DL, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Physiol 2003;285:H2500–H2509.PubMedGoogle Scholar
  95. 95.
    Baumann R, Casaulta C, Simon D, et al. Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway. FASEB J 2003;17:2221–2230.PubMedGoogle Scholar
  96. 96.
    Bozza FA, Gomes RN, Japiassu AM, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004;22:309–313.PubMedGoogle Scholar
  97. 97.
    Eriandsson Harris H, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol 2004;34:1503–1512.Google Scholar
  98. 98.
    Wang H, Yang H. Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 2004;255:320–331.PubMedGoogle Scholar
  99. 99.
    Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 2004;101:296–301.PubMedGoogle Scholar
  100. 100.
    Riedermann NC, Guo RF, Ward PA. Novel strategies for the treatment of septic shock. Nat Med 2003;9:517–524.Google Scholar
  101. 101.
    Bouchon A, Facchetti F, Weigand MA, et al. TREM-1 amplifies inflammation and is crucial mediator of septic shock. Nature 2001;410:1103–1107.PubMedGoogle Scholar
  102. 102.
    Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for NOD-1 in host recognition of peptidoglycan containing diaminopimelic acid. Nat Immunol 2003;4:702–707.PubMedGoogle Scholar
  103. 103.
    Borovikova LV, Ivanov S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000;405:458–462.PubMedGoogle Scholar
  104. 104.
    Nishio K, Akai Y, Murao Y, et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 1997;25:953–957.PubMedGoogle Scholar
  105. 105.
    Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001;345:588–595.PubMedGoogle Scholar
  106. 106.
    Zimmermann GA, Mclntyre TM, Prescott SM, et al. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002;30(suppl):S294–S301.Google Scholar
  107. 107.
    Shoemaker WC, Montgomery ES, Kaplan E, et al. Physiologic patterns in surviving and non-surviving shock patients. Arch Surg 1973;106:630.PubMedGoogle Scholar
  108. 108.
    Fink M. Cytotoxic hypoxia in sepsis. Acta Anaesthesiol Scand 1997;110:87–95.Google Scholar
  109. 109.
    Hayes MA, Timmins AC, Yau EHS, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl JMed 1994;330:1717.Google Scholar
  110. 110.
    Rivers E, Nguyen B, Havstadt S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368–1377.PubMedGoogle Scholar
  111. 111.
    Marshall JC, Foster D, Vincent JL, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the Medic trial. J Infect Dis 2004;190:527–534.PubMedGoogle Scholar
  112. 112.
    Sriskandan S, Moyes D, Cohen J. Detection of circulating bacterial superantigen and lymphotoxin alpha in patients with streptococcal toxic-shock syndrome. Lancet 1986;348:1315.Google Scholar
  113. 113.
    Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733–740.PubMedGoogle Scholar
  114. 114.
    Damas P, Ledoux D, Nys M, et al. Cytokine serum levels during severe sepsis in humans: IL-6 as a marker of severity. Ann Surg 1992;215:356.PubMedGoogle Scholar
  115. 115.
    Fisher CJ, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double blind, placebo-controlled trial. JAMA 1994;271:1836–1843.PubMedGoogle Scholar
  116. 116.
    Karzai W, Oberhoffer M, Meier-Helmann A, et al. Procalcitonin: a new indicator of systemic response to severe infections. Infection 1997;6:629–634.Google Scholar
  117. 117.
    Gendrel D, Assicot M, Raymond J, et al. Procalcitonin as a marker for the early diagnosis of neonatal infection. J Pediatr 1996;128:570–573.PubMedGoogle Scholar
  118. 118.
    deWerra I, Jacchard C, Corradin SB, et al. Cytokines, nitrite/ nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentration: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997;25:607–615.Google Scholar
  119. 119.
    Drakulovic MB, Torres A, Bauer TT, et al. Supine body position as a risk factor for nosocominal pneumonia in mechanically ventilated patients: a randomised trial. Lancet 1999;354:1851–1858.PubMedGoogle Scholar
  120. 120.
    ARDS-Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301.Google Scholar
  121. 121.
    Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomized controlled trials. BMJ 1998;317:235–240.Google Scholar
  122. 122.
    Wilkes MM, Navickis RJ. Patient survival after human albumin administration. Ann Intern Med 2001;135:149–164.PubMedGoogle Scholar
  123. 123.
    Finfers, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004;350:2247–2256.Google Scholar
  124. 124.
    Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993;103:1826.PubMedGoogle Scholar
  125. 125.
    Kellum J, Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1752–1758.Google Scholar
  126. 126.
    Marin C, Eon B, Saux P, et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18:282.PubMedGoogle Scholar
  127. 127.
    Holmes CL, Patel BM, Russell JA, et al. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989–1002.PubMedGoogle Scholar
  128. 128.
    Spronk PF, Ince C, Gardien MJ et al. Nitroglycerin in septic shock after intravascular fluid resuscitation. Lancet 2002;360:1395–1396.PubMedGoogle Scholar
  129. 129.
    Wu W, Rathore SS, Wang Y, et al. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 2001;345:1230–1236.PubMedGoogle Scholar
  130. 130.
    Corwin HL, Gettinger A, Rodriguez RM, et al. Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 1999;27:2346–2350.PubMedGoogle Scholar
  131. 131.
    Weiskopf RB, Viely MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA 1998;279:217–221.PubMedGoogle Scholar
  132. 132.
    Hebert PC, Wells G, Blajchman M, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409–417.PubMedGoogle Scholar
  133. 133.
    Kudsk KA, Croce MA, Fabian TC, et al. Enteral versus parenteral feeding: effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg 1992;15:503–508.Google Scholar
  134. 134.
    Bower RH, Cerra FB, Bershadshy B, et al. Early enteral administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter prospective, randomized, clinical trial. Crit Care Med 1995;23:436–442.PubMedGoogle Scholar
  135. 135.
    Kluger MJ, Kozak W, Conn C, et al. The adaptive value of fever. Infect Dis Clin North Am 1996;10:1–22.PubMedGoogle Scholar
  136. 136.
    Jiang Q, Cross AS, Singh IS, et al. Febrile core temperature is essential for optimal host defense in bacterial peritonitis. Infect Immun 2000;68:1265–1270.PubMedGoogle Scholar
  137. 137.
    Ribeiro SP, Chu E, Slutsky AS. Heat stress after injection of LPS in rats decreases mortality. Am J Respir Crit Care Med 1996;153:A252.Google Scholar
  138. 138.
    O’Donnell J, Axelrod R, Fisher C, et al. Use and effectiveness of hypothermia blankets for febrile patients in the intensive care unit. Clin Infect Dis 1997;24:1208–1211.PubMedGoogle Scholar
  139. 139.
    Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Critical Care 2001;5:189–195.PubMedGoogle Scholar
  140. 140.
    Ibrahim EM, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of blood stream infection on patient outcomes in the ICU setting. Chest 2000;118:146–155.PubMedGoogle Scholar
  141. 141.
    Rao AK, Chouhan V, Chen X, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 2002;48:1156–1161.Google Scholar
  142. 142.
    van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1349–1346.Google Scholar
  143. 143.
    Annane D, Sebille V, Charpentier C, et al. Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862–871.PubMedGoogle Scholar
  144. 144.
    Schroeder S, Wichers M, Klingmuller D, et al. The hypothalamic-pituitary-adrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001;29:310–316.PubMedGoogle Scholar
  145. 145.
    Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of “low dose” hydrocortisone in septic shock. A double-blind, randomized, placebo-controlled crossover study. Am J Respir Crit Care Med 2003;167:512–520.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Steven M. Opal
    • 1
  1. 1.Infectious Disease Division, Department of MedicineBrown Medical SchoolProvidenceUSA

Personalised recommendations